Hikma Pharmaceuticals: 10‑Year Decline, Market‑Cap Highlights & Growth Outlook
Hikma Pharmaceuticals PLC: 10‑year investor loss of 25.6% amid a growing pharma market in mTOR inhibitors, glycopeptide antibiotics, and quinolones.
2 minutes to read
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals Reports Strong Start to 2025 Despite Legal Challenges, Eyes Continued Growth
Hikma Pharmaceuticals PLC has reported a 6% year-over-year increase in group revenue, with a positive outlook for the remainder of 2025, driven by strong demand across various segments and geographies.
3 minutes to read